Document is current
Any future updates will be listed below
-
Authors
Sa, Jason K. https://orcid.org/0000-0002-3251-5004
Chang, Nakho
Lee, Hye Won
Cho, Hee Jin
Ceccarelli, Michele
Cerulo, Luigi
Yin, Jinlong
Kim, Sung Soo
Caruso, Francesca P.
Lee, Mijeong
Kim, Donggeon
Oh, Young Taek
Lee, Yeri
Her, Nam-Gu
Min, Byeongkwi
Kim, Hye-Jin
Jeong, Da Eun
Kim, Hye-Mi
Kim, Hyunho
Chung, Seok
Woo, Hyun Goo
Lee, Jeongwu
Kong, Doo-Sik
Seol, Ho Jun
Lee, Jung-Il
Kim, Jinho
Park, Woong-Yang
Wang, Qianghu
Sulman, Erik P.
Heimberger, Amy B.
Lim, Michael
Park, Jong Bae
Iavarone, Antonio
Verhaak, Roel G. W.
Nam, Do-Hyun
- License Information
-
More Information
Article History
Received: 22 October 2019
Accepted: 7 August 2020
First Online: 26 August 2020
Ethics approval and consent to participate
: The study was approved by the local committee of Samsung Medical Center (SMC), Seoul, Republic of Korea (IRB file #200505001 and #201004004), on the use of human samples for experimental studies. Written informed consents were provided by the participants prior to enrollment. All experimental methods abided by the principles of the Helsinki Declaration.
: Do-Hyun Nam is founder & CEO of AIMEDBIO Inc. and hold ownership equity in the company. The terms of this arrangement have been reviewed and approved by the Office of R&BD at Samsung Medical Center, in accordance with its conflict of interest policies. Antonio Iavarone declares a potential financial conflict of interest through consultancy in AIMEDBIO Inc. Nam-Gu Her, Byeongkwi Min, and Hye-Jin Kim are under paid employment by AIMEDBIO Inc. The remaining authors declare that they have no competing interests.
